How to Get Jatenzo in Pennsylvania

What Jatenzo Is and Why It Matters for Pennsylvania Patients

Jatenzo is the first oral testosterone undecanoate capsule approved by the FDA for adult males with conditions associated with a deficiency or absence of endogenous testosterone [1]. Before its March 2019 approval, testosterone replacement therapy (TRT) in the United States required injections, transdermal gels, or implantable pellets. Oral delivery changes the calculus for patients who cannot tolerate needles or who want a discreet daily option.

How Oral Testosterone Undecanoate Works

The drug uses a lipid-based self-emulsifying formulation that promotes lymphatic absorption, bypassing first-pass hepatic metabolism [2]. This mechanism separates Jatenzo from older oral androgens like methyltestosterone, which carried significant hepatotoxicity risk. In the key registration trial by Swerdloff et al. (N=166), 87% of men achieved a mean testosterone concentration within the eugonadal range (300 to 1,100 ng/dL) by day 90, with dose titration [3].

Why Pennsylvania Access Requires Specific Steps

Because Jatenzo is a Schedule III controlled substance under the Controlled Substances Act [4], Pennsylvania prescribers must hold an active DEA registration. The state also classifies testosterone products under its Prescription Drug Monitoring Program (PDMP), meaning every dispensing event is reported to the Pennsylvania Department of Health [5]. These requirements don't block access, but they add administrative steps compared to non-controlled medications.

Step 1: Confirm a Diagnosis of Male Hypogonadism

Jatenzo is FDA-indicated for adult men with hypogonadism caused by conditions such as Klinefelter syndrome, pituitary disorders, chemotherapy-related testicular failure, or cryptorchidism [1]. Off-label prescribing for age-related testosterone decline is common but not universally covered by insurance.

Required Laboratory Tests

The Endocrine Society Clinical Practice Guideline (2018) recommends confirming hypogonadism with two morning serum total testosterone measurements below 300 ng/dL, drawn between 7:00 and 10:00 AM [6]. Pennsylvania insurers almost always require both values for prior authorization.

A standard pre-Jatenzo lab panel includes:

• Total testosterone (two separate AM draws)
• Free testosterone (equilibrium dialysis preferred)
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to differentiate primary from secondary hypogonadism
• Complete blood count (CBC) with hematocrit baseline
• Hepatic function panel (AST, ALT, bilirubin)
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• PSA for men over 40 [6]

Cardiovascular Risk Screening

The FDA added a boxed warning to all testosterone products in 2015 following meta-analyses showing potential cardiovascular risk [7]. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement did not increase the incidence of major adverse cardiovascular events compared to placebo over a median follow-up of 33 months (hazard ratio 0.99; 95% CI 0.81 to 1.21) [8]. Pennsylvania clinicians should still assess baseline cardiovascular risk per the AHA/ACC guidelines, particularly in men over 65 [9].

Step 2: Find a Prescriber in Pennsylvania

Pennsylvania law permits MDs, DOs, and certified registered nurse practitioners (CRNPs) with a collaborative agreement to prescribe Schedule III controlled substances [5]. Physician assistants (PAs) may also prescribe under supervising physician protocols. The practical options break down into three categories.

In-Person Specialists

Endocrinologists and urologists are the most common Jatenzo prescribers. The American Association of Clinical Endocrinology (AACE) maintains a provider directory at aace.com that filters by state [10]. Large health systems in Pennsylvania, including UPMC, Penn Medicine, and Geisinger, have dedicated men's health or endocrinology clinics that prescribe Jatenzo.

Telehealth Prescribers

Pennsylvania enacted Act 15 of 2020, which codified telehealth parity and permits prescribing controlled substances via audio-video visits as long as the prescriber is licensed in the state [11]. After the DEA finalized its post-COVID telemedicine rule in 2025, a patient-prescriber relationship can be established via video for Schedule III, V substances without a prior in-person exam [12]. This means a Pennsylvania-licensed physician conducting a video consultation can order labs, evaluate results, and prescribe Jatenzo without requiring an office visit.

Primary Care Physicians

Many PCPs are comfortable managing straightforward TRT. A 2021 survey published in the Journal of the Endocrine Society found that 58% of testosterone prescriptions in the U.S. Originated from primary care rather than specialty clinics [13]. If your PCP is hesitant, asking for a referral to an endocrinologist or a telehealth TRT provider is a reasonable next step.

Step 3: Manage Prior Authorization in Pennsylvania

Most commercial plans and Pennsylvania Medicaid require prior authorization (PA) for Jatenzo. The branded drug carries a wholesale acquisition cost (WAC) of approximately $650, $750 per month, which motivates payer gatekeeping [14].

Documents Insurers Typically Require

A prior authorization submission in Pennsylvania generally needs:

1. Two documented morning testosterone levels below 300 ng/dL (some plans use 250 ng/dL)
2. ICD-10 diagnosis code (E29.1 for testicular hypofunction is most common)
3. Clinical rationale for oral formulation over injectable testosterone cypionate
4. CBC with hematocrit confirming baseline below 54%
5. Completed payer-specific PA form (varies by insurer)

The American Urological Association notes that insurers frequently deny first-line Jatenzo requests and require documentation of injectable TRT intolerance or contraindication before approving the oral formulation [15].

Pennsylvania Medicaid

Pennsylvania Medicaid, administered through managed care organizations (MCOs) such as UPMC for You, Highmark Wholecare, and AmeriHealth Caritas, covers Jatenzo for male hypogonadism with prior authorization [11]. Approval timelines vary: standard requests take up to 15 business days, while urgent requests receive a 24-hour turnaround.

Appeals

If denied, Pennsylvania insurance regulations require the MCO to provide a written denial reason and instructions for appeal within 30 days [11]. Peer-to-peer review, in which the prescriber discusses the case directly with the insurer's medical director, overturns roughly 40 to 60% of initial TRT denials based on published payer data [15].

Step 4: Choose a Pharmacy

Pennsylvania offers several pharmacy pathways for obtaining Jatenzo or compounded oral testosterone undecanoate.

Retail and Specialty Pharmacies

Jatenzo (brand) is stocked at most specialty pharmacies and can be ordered by retail chains including CVS, Rite Aid, and Walgreens locations across Pennsylvania. Because it is a Schedule III drug, refills are limited to five within six months of the original prescription date under federal law [4].

503A Compounding Pharmacies

Pennsylvania-licensed 503A pharmacies can compound oral testosterone undecanoate capsules for individual patients with a valid prescription [16]. Compounded versions cost significantly less than the branded product, often $80, $200 per month depending on dose and pharmacy. The Pennsylvania State Board of Pharmacy oversees 503A compounders and requires compliance with USP <795> standards for non-sterile compounding [5].

Mail-Order and Shipping

Both branded Jatenzo and compounded oral testosterone undecanoate can be shipped within Pennsylvania. Schedule III substances may be mailed via USPS or shipped via private carriers (UPS, FedEx) under DEA regulations, provided the pharmacy uses compliant packaging and signature confirmation [4]. Typical delivery time is 3 to 7 business days after pharmacy processing.

Dosing and Monitoring After You Start

The FDA-approved starting dose is 237 mg taken twice daily with food [1]. Serum testosterone should be measured after approximately 2 to 4 weeks. If the trough testosterone level is below 300 ng/dL or above 1,050 ng/dL, the dose is adjusted in 79 mg increments (one capsule). The available capsule strengths are 158 mg, 198 mg, and 237 mg [1].

Ongoing Lab Monitoring

The Endocrine Society recommends monitoring at 3 months, 6 months, and then annually [6]:

| Test | Frequency | Target | |------|-----------|--------| | Total testosterone | 3, 6, 12 months, then annually | 300 to 1,000 ng/dL (trough) | | Hematocrit/CBC | Same schedule | <54% | | PSA | Baseline, 3 to 6 months, then annually (men >40) | No rise >1.4 ng/mL per year | | Hepatic panel | 3, 6 months | ALT/AST within normal limits | | Lipid panel | 6 to 12 months | Per ACC/AHA thresholds | | Blood pressure | Every visit | <130/80 mmHg per AHA [9] |

Blood Pressure Considerations

Jatenzo's prescribing information carries a warning about dose-related increases in systolic blood pressure. In the open-label extension study, mean systolic BP increased by 3 to 5 mmHg at the 396 mg twice-daily dose [1]. The Swerdloff et al. Trial reported that 7.8% of subjects experienced BP increases exceeding 20 mmHg systolic from baseline [3]. Patients with pre-existing hypertension should have BP monitored at every follow-up visit. The AHA defines stage 1 hypertension as systolic 130 to 139 mmHg or diastolic 80 to 89 mmHg [9].

Hematocrit Management

Testosterone stimulates erythropoiesis. A hematocrit exceeding 54% requires dose reduction or temporary discontinuation per the Endocrine Society guideline [6]. A 2020 meta-analysis in the Journal of Clinical Endocrinology & Metabolism found that oral testosterone undecanoate produced smaller hematocrit elevations than injectable testosterone cypionate (mean increase 2.1% vs. 3.8%) [17].

Transferring a Jatenzo Prescription to Pennsylvania

If you're relocating to Pennsylvania from another state, your existing Jatenzo prescription can be transferred. Pennsylvania Board of Pharmacy regulations permit the transfer of Schedule III, V prescriptions between pharmacies, including across state lines, as long as the receiving pharmacy verifies the prescription with the originating pharmacy [5]. The key restriction: a controlled substance prescription can only be transferred once under federal law [4]. If you plan to use a new prescriber in Pennsylvania, having your medical records (including lab work and diagnosis documentation) sent ahead of time reduces delays.

Cost-Reduction Strategies

Branded Jatenzo without insurance typically runs $650, $900 per month at retail pharmacy prices [14]. Several strategies can lower out-of-pocket costs for Pennsylvania residents.

Manufacturer Savings Programs

Tolmar offers a copay savings card for commercially insured patients that may reduce copays to as little as $0, $75 per month, depending on plan structure. This program does not apply to government-funded insurance (Medicaid, Medicare, TRICARE) [14].

Compounded Oral Testosterone Undecanoate

As noted above, 503A compounding pharmacies in Pennsylvania can prepare oral testosterone undecanoate capsules at substantially lower cost. Patients should confirm that their compounding pharmacy holds a current Pennsylvania Board of Pharmacy license and follows USP <795> non-sterile compounding standards [16].

Patient Assistance Programs

Patients without insurance or with high deductibles may qualify for Tolmar's patient assistance program or independent nonprofit foundations that cover TRT costs. NeedyMeds and RxAssist maintain updated databases of available programs [14].

Pennsylvania-Specific Regulatory Considerations

PDMP Reporting

Every Jatenzo dispensing is reported to Pennsylvania's PDMP (ABC-MAP, Achieving Better Care by Monitoring All Prescriptions). Prescribers must query the PDMP before issuing a new testosterone prescription, though this adds only a few minutes to the clinical workflow [5].

Telehealth Follow-Up Rules

Pennsylvania Act 15 of 2020 does not require periodic in-person visits for ongoing controlled substance management as long as the prescriber maintains an active patient relationship via telehealth [11]. This means Pennsylvania patients can continue receiving Jatenzo refills through telehealth indefinitely, provided monitoring labs are completed and reviewed.

Scope of Practice

CRNPs in Pennsylvania operate under collaborative agreements with physicians but can independently prescribe Schedule III substances under their agreement terms [5]. Physician assistants prescribe under supervising physician protocols. Both provider types routinely manage TRT in Pennsylvania's health systems and telehealth platforms.